News
Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...
FDA Commissioner Marty Makary talks about his plans to revamp drug development and reduce ‘conflicts of interest’ between the ...
Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...
The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...
Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...
Novo Nordisk, the Danish maker of Ozempic and Wegovy, announced Tuesday that it has asked the Food and Drug Administration to ...
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...
Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...
Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results